University of California San Francisco

Ryutaro Hirose, MD
Ryutaro
Hirose
MD

Professor of Surgery 
Division of Transplant Surgery
Vice Chair of Clinical Operations and Value
Associate Program Director,
UCSF General Surgery Residency Program
Surgical Medical Director, Scientific Registry of Transplant Recipients (SRTR).

Address

505 Parnassus Avenue, #M884B

San Francisco, CA 94117

United States

Email: [email protected]

Phone: 415-353-8783

Fax: 415-353-8974

Biography

Dr. Ryutaro Hirose is a transplant surgeon who performs liver, kidney and pancreas transplants. Hirose's research interests include the induction of immunologic tolerance, immune monitoring and cancer in transplant patients. He has received research grants from the National Kidney Foundation and UCSF School of Medicine. Hirose earned his medical degree from Vagelos College of Physicians and Surgeons, the medical school of Columbia University. He completed clinical research training at UCSF as a resident in general surgery and a fellow in molecular medicine and transplantation surgery. Hirose is involved in teaching medical students as well as residents and fellows in surgery. He serves as associate director of UCSF's general surgery residency program.

Education

Institution Degree Dept or School End Date
University of California Diversity, Equity, and Inclusion Champion Training 2019
University of California, San Francisco Residency School of Medicine

Board Certifications

  • American Board of Surgery, 1998

Clinical Expertise

Bile Duct Injuries
Bile Duct Strictures
Bile Duct Cancer (Cholangiocarcinoma)
Complex Cancer Resections
Fulminant Hepatic Failure
Hepatitis B
Hepatitis C
Hepatocellular Carcinoma (Liver Cancer)
Kidney Transplantation
Liver Resection
Liver Transplantation
Living Donor Liver Transplantation
Living Donor Kidney Transplantation
Pancreas Transplants
Pediatric Liver Transplantation
Pediatric Kidney Transplantation
Portal Hypertension
Radio Frequency Ablation (RFA)
Surgical Shunts 

Clinical Trials

  1. Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer (NCT02081755)
    Related Conditions: Liver Cancer, Liver Transplant, Carcinoma, Hepatocellular Cancer| Start Date: | End Date:

Research Narrative

Dr. Hirose's research focus is ischemia-reperfusion injury and potential interventions to ameliorate renal and hepatic I-R injury. His group uses animal models, performs clinical and translational research as well as research on deceased donors. He collaborates with Dr. Claus Niemann, MD from the Dept. Anesthesia and they are co-Directors of the Ischemic Organ Injury Lab.

Research Interests

  • Living Donor Liver Transplantation
  • Non-melanoma Skin Cancer in Organ Transplant Patients
  • Pathogenesis of Focal Segmental Glomerulosclerosis
  • Outcomes in Renal Transplant Recipients
  • Ischemia Reperfusion Injury in Fatty Livers
  • Ischemia-reperfusion Injury in Kidneys and Hyperglycemia

Research Pathways

Basic Biomedical & Translational Research

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 120
  1. Adjusting for race in metrics of organ procurement organization performance.
    Miller JM, Zaun D, Wood NL, Lyden GR, McKinney WT, Hirose R, Snyder JJ| | View in PubMed
  2. DCD liver transplant in patients with a MELD over 35.
    Meier RPH, Nunez M, Syed SM, Feng S, Tavakol M, Freise CE, Roberts JP, Ascher NL, Hirose R, Roll GR| | View in PubMed
  3. Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome.
    Yilma M, Cogan R, Shui AM, Neuhaus JM, Light C, Braun H, Mehta N, Hirose R| | View in PubMed
  4. Geographic disparities in access to liver transplantation.
    Yilma M, Dalal N, Wadhwani SI, Hirose R, Mehta N| | View in PubMed
  5. Stakeholders' perspectives on transplant metrics: the 2022 Scientific Registry of Transplant Recipients' consensus conference.
    Snyder JJ, Schaffhausen CR, Hart A, Axelrod DA, Dils D, Formica RN, Gaber AO, Hunt HF, Jones J, Mohan S, Patzer RE, Pinney SP, Ratner LE, Slaker D, Stewart D, Stewart ZA, Van Slyck S, Kasiske BL, Hirose R, Israni AK| | View in PubMed
  6. Time to discard the term "discard".
    Hart A, Patzer RE, Spear J, Hirose R, Tabatabai A, Wood NL, Schaffhausen CR, Axelrod DA, Israni AK, Snyder JJ| | View in PubMed
  7. OPTN/SRTR 2021 Annual Data Report: COVID-19.
    Miller JM, Ahn YS, Hart A, Lindblad K, Jett C, Fox C, Hirose R, Israni AK, Snyder JJ| | View in PubMed
  8. Number of Local Regional Therapies for Hepatocellular Carcinoma and Peri-Operative Outcomes after Liver Transplantation.
    Brown AE, Shui AM, Adelmann D, Mehta N, Roll GR, Hirose R, Syed SM| | View in PubMed
  9. Toward a better distribution system: it is complicated.
    Hirose R| | View in PubMed
  10. The Reality of Inadequate Patient Care and the Need for a Global Action Framework in Organ Donation and Transplantation.
    Domínguez-Gil B, Ascher NL, Fadhil RAS, Muller E, Cantarovich M, Ahn C, Berenguer M, Bušic M, Egawa H, Gondolesi GE, Haberal M, Harris D, Hirose R, Ilbawi A, Jha V, López-Fraga M, Andrés Madera S, Najafizadeh K, O'Connell PJ, Rahmel A, Shaheen FAM, Twahir A, Van Assche K, Wang H, Haraldsson B, Chatzixiros E, Delmonico FL| | View in PubMed
  11. Assessment of Surgeon Performance of Advanced Open Surgical Skills Using a Microskills-Based Novel Curriculum.
    Greenberg AL, Karimzada MM, Brian R, Yap A, Luu HY, Ahmed S, Huang CY, Waits SA, Hirose R, Alseidi A, Rapp JH, O'Sullivan PS, Chern H, Syed SM| | View in PubMed
  12. Transplant program evaluations in the middle of the COVID-19 pandemic.
    Miller J, Lyden GR, Zaun D, Kasiske BL, Hirose R, Israni AK, Snyder JJ| | View in PubMed
  13. Toward continuous improvement of Scientific Registry of Transplant Recipients performance reporting: Advances following 2012 consensus conference and future consensus building for 2022 consensus conference.
    Israni AK, Hirose R, Segev DL, Hart A, Schaffhausen CR, Axelrod DA, Kasiske BL, Snyder JJ| | View in PubMed
  14. Pancreas Transplantation for Type 2 Diabetes: A Systematic Review, Critical Gaps in the Literature, and a Path Forward.
    Amara D, Hansen KS, Kupiec-Weglinski SA, Braun HJ, Hirose R, Hilton JF, Rickels MR, Odorico JS, Stock PG| | View in PubMed
  15. Surgical complications after living and deceased donor liver transplant: The NSQIP transplant experience.
    Amara D, Parekh J, Sudan D, Elias N, Foley DP, Conzen K, Grieco A, Braun HJ, Greenstein S, Byrd C, Ko C, Hirose R| | View in PubMed
  16. Long-term Outcomes Following Kidney and Liver Transplant in Recipients With HIV.
    Zarinsefat A, Gulati A, Shui A, Braun H, Rogers R, Hirose R, Ascher N, Stock P| | View in PubMed
  17. Toward a more efficient organ placement system (and defeating FOMO).
    Roll GR, Hirose R| | View in PubMed
  18. International Travel for Liver Transplantation: A Comprehensive Assessment of the Impact on the United States Transplant System.
    Braun HJ, Amara D, Shui AM, Stock PG, Hirose R, Delmonico FL, Ascher NL| | View in PubMed
  19. Impact of COVID-19 pandemic on the size of US transplant waiting lists.
    Miller J, Wey A, Valapour M, Hart A, Musgrove D, Hirose R, Ahn YS, Israni AK, Snyder JJ| | View in PubMed
  20. Advantages and Limitations of Clinical Scores for Donation After Circulatory Death Liver Transplantation.
    Meier RPH, Kelly Y, Yamaguchi S, Braun HJ, Lunow-Luke T, Adelmann D, Niemann C, Maluf DG, Dietch ZC, Stock PG, Kang SM, Feng S, Posselt AM, Gardner JM, Syed SM, Hirose R, Freise CE, Ascher NL, Roberts JP, Roll GR| | View in PubMed
  21. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.
    Bernards S, Hirose R, Yao FY, Jin C, Dodge JL, Huang CY, Mehta N| | View in PubMed
  22. Machine Learning Prediction of Liver Allograft Utilization From Deceased Organ Donors Using the National Donor Management Goals Registry.
    Bishara AM, Lituiev DS, Adelmann D, Kothari RP, Malinoski DJ, Nudel JD, Sally MB, Hirose R, Hadley DD, Niemann CU| | View in PubMed
  23. The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End-Stage Liver Disease Scores and Exception Statuses.
    Wey A, Noreen S, Gentry S, Cafarella M, Trotter J, Salkowski N, Segev D, Israni A, Kasiske B, Hirose R, Snyder J| | View in PubMed
  24. Equity in kidney transplant allocation - North American perspective.
    Yilma M, Hirose R| | View in PubMed
  25. Standardizing Discharge Opioid Prescriptions in Kidney Transplant Patients Decreases Opioid Usage.
    Schwab ME, Braun HJ, Quan D, Roll GR, Budanova N, Ascher NL, Hirose R| | View in PubMed
  26. Understanding the Impact of Pneumonia and Other Complications in Elderly Liver Transplant Recipients: An Analysis of NSQIP Transplant.
    Schnickel GT, Greenstein S, Berumen JA, Elias N, Sudan DL, Conzen KD, Mekeel KL, Foley DP, Hirose R, Parekh JR| | View in PubMed
  27. Live Donor Liver Transplantation in the United States: Impact of Share 35 on Live Donor Utilization.
    Braun HJ, Dodge JL, Grab JD, Schwab ME, Liu IH, Glencer AC, Stock PG, Hirose R, Roberts JP, Ascher NL| | View in PubMed
  28. Mortality among solid organ waitlist candidates during COVID-19 in the United States.
    Miller J, Wey A, Musgrove D, Son Ahn Y, Hart A, Kasiske BL, Hirose R, Israni AK, Snyder JJ| | View in PubMed
  29. Setting rules for the sandbox: A response to "Successfully sharing the sandbox: A perspective on combined DCD liver and heart donor procurement".
    Wisel SA, Thiessen C, Day R, Belin LJ, Syed SM, Hirose R, Ascher N, Roberts JP, Freise CE| | View in PubMed
  30. Metastatic Donor-derived Malignancies Following Simultaneous Pancreas-kidney Transplant: Three Case Reports and Management Strategies.
    Amara D, Wisel SA, Braun HJ, Collisson EA, Friedlander T, Worner G, Roll GR, Hirose R, Stock PG| | View in PubMed
  31. Opioid use prior to liver transplant is associated with increased risk of death after transplant.
    Braun HJ, Schwab MP, Jin C, Amara D, Mehta NJ, Grace TR, Croci R, Freise CE, Roberts JP, Hirose R, Ascher NL| | View in PubMed
  32. COVID-19 and Abdominal Transplant: A Stepwise Approach to Practice During Pandemic Conditions.
    Syed SM, Gardner J, Roll G, Webber A, Mehta N, Shoji J, Adelmann D, Niemann C, Braun HJ, Mello A, Yao F, Posselt A, Kang SM, Hirose R, Roberts J, Feng S, Ascher N, Stock P, Freise C| | View in PubMed
  33. Contemporary Management of Hepatic Cyst Disease: Techniques and Outcomes at a Tertiary Hepatobiliary Center.
    Gomez A, Wisneski AD, Luu HY, Hirose K, Roberts JP, Hirose R, Freise CE, Nakakura EK, Corvera CU| | View in PubMed
  34. Early national and center-level changes to kidney transplantation in the United States during the COVID-19 epidemic.
    Boyarsky BJ, Werbel WA, Durand CM, Avery RK, Jackson KR, Kernodle AB, Snyder J, Hirose R, Massie IM, Garonzik-Wang JM, Segev DL, Massie AB| | View in PubMed
  35. Implementing an opioid reduction protocol in renal transplant recipients.
    Schwab ME, Braun HJ, Ascher NL, Hirose R| | View in PubMed
  36. A Virtual Crossmatch-based Strategy Facilitates Sharing of Deceased Donor Kidneys for Highly Sensitized Recipients.
    Roll GR, Webber AB, Gae DH, Laszik Z, Tavakol M, Mayen L, Cunniffe K, Syed S, Hirose R, Freise C, Feng S, Roberts JP, Ascher NL, Stock PG, Rajalingam R| | View in PubMed
  37. A model for the institutional adoption of innovative surgical techniques.
    Jain M, Duh QY, Hirose R, Sosa JA, Suh I| | View in PubMed
  38. Balancing Efficiency and Fairness in Liver Transplant Access: Tradeoff Curves for the Assessment of Organ Distribution Policies.
    Bertsimas D, Papalexopoulos T, Trichakis N, Wang Y, Hirose R, Vagefi PA| | View in PubMed
  39. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change.
    Brondfield MN, Dodge JL, Hirose R, Heimbach J, Yao FY, Mehta N| | View in PubMed
  40. The Centers for Medicare and Medicaid Services' proposed metrics for recertification of organ procurement organizations: Evaluation by the Scientific Registry of Transplant Recipients.
    Snyder JJ, Musgrove D, Zaun D, Wey A, Salkowski N, Rosendale J, Israni AK, Hirose R, Kasiske BL| | View in PubMed
  41. The rise and fall of the model for end-stage liver disease score and the need for an optimized machine learning approach for liver allocation.
    Vagefi PA, Bertsimas D, Hirose R, Trichakis N| | View in PubMed
  42. Long-term follow-up of beta cell replacement therapy in 10 HIV-infected patients with renal failure secondary to type 1 diabetes mellitus.
    Roll GR, Posselt AM, Freise J, Baird J, Syed S, Mo Kang S, Hirose R, Szot GL, Zarinsefat A, Feng S, Worner G, Sarwal M, Stock PG| | View in PubMed
  43. Beyond death and graft survival-Variation in outcomes after kidney transplantation. Results from the NSQIP Transplant beta phase.
    Parekh JR, Hirose R, Foley DP, Grieco A, Cohen ME, Hall BL, Ko CY, Greenstein S| | View in PubMed
  44. Changes in Simultaneous Liver-kidney Transplant Allocation Policy May Impact Postliver Transplant Outcomes.
    Cullaro G, Hirose R, Lai JC| | View in PubMed
  45. Beyond death and graft survival-Variation in outcomes after liver transplant. Results from the NSQIP transplant beta phase.
    Parekh JR, Greenstein S, Sudan DL, Grieco A, Cohen ME, Hall BL, Ko CY, Hirose R| | View in PubMed
  46. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.
    Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY| | View in PubMed
  47. State-Based Liver Allocation: Is It a Viable Alternative?
    Hirose R| | View in PubMed
  48. Association of HLA Antigen Mismatch With Risk of Developing Skin Cancer After Solid-Organ Transplant.
    Gao Y, Twigg AR, Hirose R, Roll GR, Nowacki AS, Maytin EV, Vidimos AT, Rajalingam R, Arron ST| | View in PubMed
  49. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
    Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE| | View in PubMed
  50. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.
    Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | View in PubMed
  51. Development and validation of an optimized prediction of mortality for candidates awaiting liver transplantation.
    Bertsimas D, Kung J, Trichakis N, Wang Y, Hirose R, Vagefi PA| | View in PubMed
  52. Report of National Kidney Foundation Consensus Conference to Decrease Kidney Discards.
    Cooper M, Formica R, Friedewald J, Hirose R, O'Connor K, Mohan S, Schold J, Axelrod D, Pastan S| | View in PubMed
  53. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
    Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY| | View in PubMed
  54. How Good Is Good? Benchmarking and the Quest for Quality Improvement in Liver Transplantation.
    Patel MS, Hirose R, Vagefi PA| | View in PubMed
  55. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form.
    Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | View in PubMed
  56. Defining disparities in liver transplantation: The devil is in the details.
    Hirose R, Heimbach J| | View in PubMed
  57. Liver allocation and distribution: time for a change.
    Deshpande R, Hirose R, Mulligan D| | View in PubMed
  58. Predicting Outcomes on the Liver Transplant Waiting List in the United States: Accounting for Large Regional Variation in Organ Availability and Priority Allocation Points.
    Hart A, Schladt DP, Zeglin J, Pyke J, Kim WR, Lake JR, Roberts JP, Hirose R, Mulligan DC, Kasiske BL, Snyder JJ, Israni AK| | View in PubMed
  59. Resolving Misconceptions About Liver Allocation and Redistricting Methodology.
    Gentry SE, Hirose R, Mulligan D| | View in PubMed
  60. Effect of moderately intense perioperative glucose control on renal allograft function: a pilot randomized controlled trial in renal transplantation.
    Parekh J, Roll GR, Wisel S, Rushakoff RJ, Hirose R| | View in PubMed
  61. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
    Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH| | View in PubMed
  62. The impact of broader regional sharing of livers: 2-year results of "Share 35".
    Edwards EB, Harper AM, Hirose R, Mulligan DC| | View in PubMed
  63. Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy?
    Mehta N, Heimbach J, Hirose R, Roberts JP, Yao FY| | View in PubMed
  64. Impact of a quality improvement project on deceased organ donor management.
    Olmos A, Feiner J, Hirose R, Swain S, Blasi A, Roberts JP, Niemann CU| | View in PubMed
  65. Robust Models Support Redistricting Liver Allocation to Reduce Geographic Disparity.
    Gentry SE, Segev DL, Kasiske BL, Mulligan DC, Hirose R| | View in PubMed
  66. Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function.
    Niemann CU, Feiner J, Swain S, Bunting S, Friedman M, Crutchfield M, Broglio K, Hirose R, Roberts JP, Malinoski D| | View in PubMed
  67. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.
    Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK, Roberts JP| | View in PubMed
  68. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.
    Heimbach JK, Hirose R, Stock PG, Schladt DP, Xiong H, Liu J, Olthoff KM, Harper A, Snyder JJ, Israni AK, Kasiske BL, Kim WR| | View in PubMed
  69. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list.
    Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY| | View in PubMed
  70. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
    Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY| | View in PubMed
  71. Immunosuppression: Conventions and controversies.
    Mehta N, Hirose R| | View in PubMed
  72. Peri-operative hyperglycemia is associated with delayed graft function in deceased donor renal transplantation.
    Parekh J, Roll GR, Feng S, Niemann CU, Hirose R| | View in PubMed
  73. Sorafenib combined with locoregional therapy prior to liver transplantation for hepatocellular carcinoma: an update on a previous case report.
    Vagefi PA, Hirose R| | View in PubMed
  74. Director of anesthesiology for liver transplantation: existing practices and recommendations by the United Network for Organ Sharing.
    Mandell MS, Pomfret EA, Steadman R, Hirose R, Reich DJ, Schumann R, Walia A| | View in PubMed
  75. Native renal function after combined liver-kidney transplant for type 1 hepatorenal syndrome: initial report on the use of postoperative Technetium-99 m-mercaptoacetyltriglycine scans.
    Vagefi PA, Qian JJ, Carlson DM, Aparici CM, Hirose R, Vincenti F, Wojciechowski D| | View in PubMed
  76. Fitzpatrick skin phototype is an independent predictor of squamous cell carcinoma risk after solid organ transplantation.
    Gogia R, Binstock M, Hirose R, Boscardin WJ, Chren MM, Arron ST| | View in PubMed
  77. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma.
    Park SJ, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, Vagefi PA| | View in PubMed
  78. Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial.
    Kelley RK, Hirose R, Venook AP| | View in PubMed
  79. Validity of patient skin cancer report among organ transplant recipients.
    Dybbro E, Mihalis E, Hirose R, Arron ST| | View in PubMed
  80. Intraoperative hyperglycemia augments ischemia reperfusion injury in renal transplantation: a prospective study.
    Parekh J, Niemann CU, Dang K, Hirose R| | View in PubMed
  81. HLA-DR matching in organ allocation: balance between waiting time and rejection in pediatric kidney transplantation.
    Vu LT, Baxter-Lowe LA, Garcia J, McEnhill M, Summers P, Hirose R, Lee M, Stock PG| | View in PubMed
  82. Novel strategies in immunosuppression: issues in perspective.
    Webber A, Hirose R, Vincenti F| | View in PubMed
  83. Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?
    Vagefi PA, Hirose R| | View in PubMed
  84. Donor pre-treatment with everolimus or cyclosporine does not reduce ischaemia-reperfusion injury in a rat kidney transplant model.
    Martinez-Palli G, Hirose R, Liu T, Xu F, Dang K, Feiner J, Serkova NJ, Niemann CU| | View in PubMed
  85. Hepatic surgery at a VA tertiary medical center: lessons learned.
    Alemi F, Kwon E, Freise C, Kang SM, Hirose R, Stewart L, Corvera CU| | View in PubMed
  86. Induction of intestinal ischemia reperfusion injury by portal vein outflow occlusion in rats.
    Vincenti M, Behrends M, Dang K, Park YH, Hirose R, Blasi-Ibanez A, Liu T, Serkova NJ, Niemann CU| | View in PubMed
  87. Kidney transplantation at UCSF: 8,300 transplants and onward.
    Wojciechowski D, Hirose R, Stock P, Vincenti F, Baxter-Lowe LA, Salvatierra O| | View in PubMed
  88. Short passive cooling protects rats during hepatectomy by inducing heat shock proteins and limiting the induction of pro-inflammatory cytokines.
    Niemann CU, Xu F, Choi S, Behrends M, Park Y, Hirose R, Maher JJ| | View in PubMed
  89. Acute hyperglycemia worsens hepatic ischemia/reperfusion injury in rats.
    Behrends M, Martinez-Palli G, Niemann CU, Cohen S, Ramachandran R, Hirose R| | View in PubMed
  90. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin.
    Niemann CU, Walia A, Waldman J, Davio M, Roberts JP, Hirose R, Feiner J| | View in PubMed
  91. Predictors associated with terminal renal function in deceased organ donors in the intensive care unit.
    Blasi-Ibanez A, Hirose R, Feiner J, Freise C, Stock PG, Roberts JP, Niemann CU| | View in PubMed
  92. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.
    Yao FY, Kerlan RK, Hirose R, Davern TJ, Bass NM, Feng S, Peters M, Terrault N, Freise CE, Ascher NL, Roberts JP| | View in PubMed
  93. Alterations in the proteome of pulmonary alveolar type II cells in the rat after hepatic ischemia-reperfusion.
    Hirsch J, Niemann CU, Hansen KC, Choi S, Su X, Frank JA, Fang X, Hirose R, Theodore P, Sapru A, Burlingame AL, Matthay MA| | View in PubMed
  94. Transient hyperglycemia affects the extent of ischemia-reperfusion-induced renal injury in rats.
    Hirose R, Xu F, Dang K, Liu T, Behrends M, Brakeman PR, Wiener-Kronish J, Niemann CU| | View in PubMed
  95. Liver transplantation at UCSF--a 20-year experience.
    Hirose R, Yao F, Stock P, Roberts J, Ascher N| | View in PubMed
  96. Increased severity of renal ischemia-reperfusion injury with venous clamping compared to arterial clamping in a rat model.
    Park Y, Hirose R, Dang K, Xu F, Behrends M, Tan V, Roberts JP, Niemann CU| | View in PubMed
  97. Remote renal injury following partial hepatic ischemia/reperfusion injury in rats.
    Behrends M, Hirose R, Park YH, Tan V, Dang K, Xu F, Park SH, Niemann CU| | View in PubMed
  98. Ischemia-reperfusion injury is more severe in older versus young rat livers.
    Park Y, Hirose R, Coatney JL, Ferrell L, Behrends M, Roberts JP, Serkova NJ, Niemann CU| | View in PubMed
  99. Immunosuppression: today, tomorrow, and withdrawal.
    Hirose R, Vincenti F| | View in PubMed
  100. Mild hypothermia reduces the inflammatory response and hepatic ischemia/reperfusion injury in rats.
    Behrends M, Hirose R, Serkova NJ, Coatney JL, Bedolli M, Yardi J, Park YH, Niemann CU| | View in PubMed
  101. Mild hypothermia protects obese rats from fulminant hepatic necrosis induced by ischemia-reperfusion.
    Niemann CU, Choi S, Behrends M, Hirose R, Noh J, Coatney JL, Roberts JP, Serkova NJ, Maher JJ| | View in PubMed
  102. Warm ischemia-induced alterations in oxidative and inflammatory proteins in hepatic Kupffer cells in rats.
    Hirsch J, Hansen KC, Choi S, Noh J, Hirose R, Roberts JP, Matthay MA, Burlingame AL, Maher JJ, Niemann CU| | View in PubMed
  103. Glutamine does not protect against hepatic warm ischemia/reperfusion injury in rats.
    Noh J, Behrends M, Choi S, Bedolli MA, Yardi J, Hirose R, Niemann CU| | View in PubMed
  104. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation.
    Yao FY, Hirose R, LaBerge JM, Davern TJ, Bass NM, Kerlan RK, Merriman R, Feng S, Freise CE, Ascher NL, Roberts JP| | View in PubMed
  105. Ischemic preconditioning improves energy state and transplantation survival in obese Zucker rat livers.
    Niemann CU, Hirose R, Liu T, Behrends M, Brown JL, Kominsky DF, Roberts JP, Serkova N| | View in PubMed
  106. Rapidly developing nephrocalcinosis in a patient with end-stage liver disease who received a domino liver transplant from a patient with known congenital oxalosis.
    Aziz S, Callen PW, Vincenti F, Hirose R| | View in PubMed
  107. Skin cancer as a contraindication to organ transplantation.
    Otley CC, Hirose R, Salasche SJ| | View in PubMed
  108. Metabolic profiling of livers and blood from obese Zucker rats.
    Serkova NJ, Jackman M, Brown JL, Liu T, Hirose R, Roberts JP, Maher JJ, Niemann CU| | View in PubMed
  109. Mild hypothermia provides significant protection against ischemia/reperfusion injury in livers of obese and lean rats.
    Choi S, Noh J, Hirose R, Ferell L, Bedolli M, Roberts JP, Niemann CU| | View in PubMed
  110. BKV in simultaneous pancreas-kidney transplant recipients: a leading cause of renal graft loss in first 2 years post-transplant.
    Lipshutz GS, Mahanty H, Feng S, Hirose R, Stock PG, Kang SM, Posselt AM, Freise CE| | View in PubMed
  111. The influence of portoenterostomy on transplantation for biliary atresia.
    Visser BC, Suh I, Hirose S, Rosenthal P, Lee H, Roberts JP, Hirose R| | View in PubMed
  112. Treatment and outcome of invasive bladder cancer in patients after renal transplantation.
    Master VA, Meng MV, Grossfeld GD, Koppie TM, Hirose R, Carroll PR| | View in PubMed
  113. Antitumor immunity induced by dendritic cell-based vaccination is dependent on interferon-gamma and interleukin-12.
    Hiramoto JS, Tsung K, Bedolli M, Norton JA, Hirose R| | View in PubMed
  114. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores.
    Yao FY, Saab S, Bass NM, Hirose R, Ly D, Terrault N, Lazar AA, Bacchetti P, Ascher NL, Roberts JP| | View in PubMed
  115. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study.
    Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, Terrault NA, Frassetto LA, Palefsky JM, Tomlanovich SJ, Ascher NL| | View in PubMed
  116. CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients.
    Posselt AM, Vincenti F, Bedolli M, Lantz M, Roberts JP, Hirose R| | View in PubMed
  117. Management of lymphoceles after renal transplantation: laparoscopic versus open drainage.
    Fuller TF, Kang SM, Hirose R, Feng S, Stock PG, Freise CE| | View in PubMed
  118. Successful long-term outcomes using pediatric en bloc kidneys for transplantation.
    Hiramoto JS, Freise CE, Randall HR, Bretan PN, Tomlanovich S, Stock PG, Hirose R| | View in PubMed
  119. Live donor renal transplants using kidneys with arteriographic evidence of mild renovascular disease.
    Hiramoto JS, LaBerge JM, Neymark E, Hirose R| | View in PubMed
  120. Pros and cons of using interleukin-2 receptor antibodies in liver transplant recipients.
    Hirose R| | View in PubMed